Trials / Completed
CompletedNCT00981227
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Therapy for Patients With Post-herpetic Neuralgia: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 567 (actual)
- Sponsor
- Bial - Portela C S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with post-herpetic neuralgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eslicarbazepine acetate | Scored tablets |
| DRUG | Placebo | oral route |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2009-09-22
- Last updated
- 2014-10-29
- Results posted
- 2013-05-03
Source: ClinicalTrials.gov record NCT00981227. Inclusion in this directory is not an endorsement.